Abstract:Chemotherapy has been widely used for treating the vast majority of cancer patients. Unfortunately, only a fraction of patients can respond to chemotherapies, but these patients still experience severe side effects. In this context, a wide range of nanotherapeutic platforms have been developed with the aim of improving treatment outcomes while reducing drug toxicities. Nanohydrogels are highly appealing "smart" biocompatible and biodegradable vehicles for either local or systemic delivery of bioactive com-pounds. Here, we developed prodrug hydrogelators that can undergo one-step distillation-precipitation polymerization to form systemically injectable nanohydrogels. The optimized nanohydrogels were capa-ble of rapidly releasing active agents (e.g., the cytotoxic agent cabazitaxel or the PI3K molecular inhibitor PI103) in response to the reducing tumor microenvironment, while drug release was very slow in the absence of the reductive reagent glutathione. Cabazitaxel-loaded nanogels showed preferential tumor ac-cumulation, and administration of nanogels produced durable tumor regression in a docetaxel-resistant cervical tumor xenograft-bearing mouse model. More significantly, nanogel-based therapy was proven to demonstrate a higher safety profile than solution-based free cabazitaxel. Collectively, this study provides an alternative formulation that meets the essential requirements of high stability in the blood, sponta-neous drug release at diseased sites, favorable safety in vivo , and translational capacity for further inves-tigations. Statement of significance Chemotherapy remains a considerable challenge and only a fraction of patients can respond to chemotherapies. Here we report an intratumoral reducing agent-activatable, tumor-targeting prodrug nanogel platform for therapeutic delivery. To this end, two anticancer agents (e.g., cytotoxic cabazitaxel or PI3K molecular inhibitor PI103) are tested. Prodrug nanogels are stable in the blood but performed reduction-triggered release of chemically unmodified drug molecules in cancerous tissues. Cabazitaxel-loaded nanogels exhibit satisfactory anticancer performance in a preclinical docetaxel-resistant tumor model. This is a practical and expedient approach that combines the prodrug strategy and nanogel scaf-fold to re-engineer a hydrophobic and toxic anticancer drug. The approach also is broadly applicable for the formulation of other agents to improve the therapeutic index. (c) 2021 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Nitric oxide-releasing docetaxel prodrug nanoplatforms for effective cancer therapy

Self-Delivering Prodrug-Nanoassemblies Fabricated by Disulfide Bond Bridged Oleate Prodrug of Docetaxel for Breast Cancer Therapy

Redox-sensitive prodrug nanoassemblies based on linoleic acid-modified docetaxel to resist breast cancers

Reduction-Responsive Docetaxel Prodrug Encapsulated Within Human Serum Albumin Nanoparticles for Cancer Therapy.

Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Docetaxel Prodrug Liposomes for Tumor Therapy: Characterization, in Vitro and in Vivo Evaluation

Redox-responsive Nanoparticles Based on Chondroitin Sulfate and Docetaxel Prodrug for Tumor Targeted Delivery of Docetaxel.

How Nanotechnology Can Enhance Docetaxel Therapy

Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy

Docetaxel-Loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Synthesis of biocompatible polymeric nanomaterial dually loaded with paclitaxel and nitric oxide for anti-MDR cancer therapy

Rational Engineering Docetaxel Prodrug Nanoassemblies: Response Modules Guiding Efficacy Enhancement and Toxicity Reduction

<sub>3</sub><sub>1</sub> Integrin-Targeting Polymersomal Docetaxel as an Advanced Nanotherapeutic for Nonsmall Cell Lung Cancer Treatment

Functional Biodegradable Nitric Oxide Donor-Containing Polycarbonate-Based Micelles for Reduction-Triggered Drug Release and Overcoming Multidrug Resistance.

Current Development in Nanoformulations of Docetaxel

Synthesis of Calcium Phosphate Nanoparticle‐Based Docetaxel Delivery System and Its in Vitro Anticancer Activity

Current development in nanoformulations of docetaxel.

Transferrin-targeting Ph-Responsive and Biodegradable Mesoporous Silica Nanohybrid for Nitric Oxide-Sensitized Chemotherapy of Cancer

Integrin-targeting Disulfide-Crosslinked Micellar Docetaxel Eradicates Lung and Prostate Cancer Patient-Derived Xenografts.

Paclitaxel-Paclitaxel Prodrug Nanoassembly As A Versatile Nanoplatform for Combinational Cancer Therapy

A General Prodrug Nanohydrogel Platform for Reduction-Triggered Drug Activation and Treatment of Taxane-Resistant Malignancies.